Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.
from NDTV News - Special https://ift.tt/3nX8fwP
Subscribe to:
Post Comments (Atom)
E-commerce emerges as top paymaster in 2024
In 2024, the internet and e-commerce sector led in pay across all levels, with top executives earning an average of Rs 37 lakh. Professional...
-
Collecting Lego — yes, the plastic toys made of interlocking bricks that become cars and castles and robots —returned more than large stocks...
-
from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News http://bit.ly/2VEK8DU...
-
A woman, in her early 20s, was stabbed to death by a man in southeast Delhi's Bhogal area on Friday evening, following which the accused...
No comments:
Post a Comment